Vitrolife Stock Price, News & Analysis

Vitrolife invites investors to a conference call on February 16, 2022, at 10:00 a.m. CET to discuss the Report on Operations 2021. The call will feature CEO Thomas Axelsson and CFO Patrik Tolf. Participants can register 10-15 minutes prior, using the provided international dial-in numbers. The report will be released at 8:00 a.m. CET on the same day, with presentation materials available on the company's website. A recorded version of the call will be accessible for seven days after the event.

On December 30, 2021, Vitrolife AB announced the issuance of 17,251,312 new shares following a decision made at the Extraordinary General Meeting on October 20, 2021. This increase brings the total number of shares to 135,447,190 as of the announcement date. This change is part of the company's compliance with the Swedish Financial Instruments Trading Act and aims to enhance liquidity and shareholder value.

On December 7, 2021, Vitrolife's CEO Thomas Axelsson sold 38,300 shares for approximately SEK 18.7 million. This sale leaves him with 13,000 shares remaining. Axelsson cited the positive development of the share price since his acquisition in 2012 as a reason to realize part of his profit for personal financial needs. The transaction will be reported to the Swedish Financial Supervisory Authority per regulations. This announcement is mandated under the EU Market Abuse Regulation, with details provided at 10:50 am CET.

Vitrolife AB has completed the acquisition of 100% of Igenomix S.L., following regulatory approvals. The deal includes a non-cash consideration issue that increases the total number of shares from 118,195,878 to 135,447,190, resulting in a dilution of approximately 13%. For the period from January 1 to September 30, 2021, Igenomix generated revenues of EUR 91.4 million, with an adjusted EBITDA of EUR 23.3 million. The integration of Igenomix will be effective from December 1, 2021, postponing the 2021 report on operations to February 16, 2022.

Vitrolife AB has announced a prospectus for the trading of newly issued shares on Nasdaq Stockholm. This follows a non-cash issue to acquire all shares in Mendel Holdco S.L., and indirectly in Igenomix S.L.. The total number of shares will rise by 17,251,312, increasing the share capital to SEK 27,631,226.760. Existing shareholders will experience a 12.7% dilution of their capital and votes. The prospectus is now available from the Swedish Financial Supervisory Authority and the company’s website.

Vitrolife AB announces the expansion of its genomic testing kits distribution to the Asia Pacific region (excluding China). This move follows the partnership with Illumina and requires a payment of USD 3 million for expanded rights. The commercial launch of EmbryoMap occurred in Q2 of this year, expected to generate over SEK 50 million in revenue in 2022, positively impacting earnings per share.

Vitrolife AB reported a strong financial performance for the third quarter of 2021, with sales reaching SEK 406 million, a 27% increase year-over-year. EBITDA rose to SEK 162 million, yielding a 40% margin. The company also announced the acquisition of Igenomix for EUR 1.25 billion, financed partially through a directed share issue of SEK 3.6 billion. For January to September 2021, total sales were SEK 1,167 million, up 35%, and net income increased to SEK 310 million. A non-cash share issue of SEK 6.4 billion was also approved to help fund this acquisition.

Vitrolife AB has appointed Patrik Tolf as the new CFO, effective January 1, 2022. Tolf, currently serving as interim CFO at Karolinska University Hospital, has a strong background with previous roles in finance at Volvo Car Group and Saab AB. He replaces Mikael Engblom, who will remain in the position until Tolf's start date. CEO Thomas Axelsson expressed confidence in Tolf's operational and strategic expertise to enhance the company’s growth journey.

At Vitrolife's Extraordinary General Meeting on October 20, 2021, decisions were made to facilitate the acquisition of Igenomix through a non-cash consideration issue. Additionally, Vesa Koskinen was elected as a new board member, resulting in an increase in board remuneration due to the expanded membership. These decisions are contingent upon the successful completion of the non-cash issue.